Terms: = Skin cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2 AND Treatment
16 results:
1. Genistein suppresses allergic contact dermatitis through regulating the map2k2/ERK pathway.
Xu J; Xiong H; Zhao Z; Luo M; Ju Y; Yang G; Mei Z
Food Funct; 2021 May; 12(10):4556-4569. PubMed ID: 33908440
[TBL] [Abstract] [Full Text] [Related]
2. An overview of binimetinib for the treatment of melanoma.
Specenier P
Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract] [Full Text] [Related]
4. Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Olbryt M; Pigłowski W; Rajczykowski M; Pfeifer A; Student S; Fiszer-Kierzkowska A
Target Oncol; 2020 Feb; 15(1):101-113. PubMed ID: 31980996
[TBL] [Abstract] [Full Text] [Related]
5. Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Donati M; Zelano G; Coppola R; Cinelli E; Verri M; Persichetti P; Perrella E; Devirgiliis V; Calvieri S; Crescenzi A; Panasiti V
Ital J Dermatol Venerol; 2021 Oct; 156(5):593-598. PubMed ID: 31804055
[TBL] [Abstract] [Full Text] [Related]
6. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by map2k2 and B2M mutations in melanoma.
Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
[TBL] [Abstract] [Full Text] [Related]
7. Trametinib (GSK1120212).
Zeiser R; Andrlová H; Meiss F
Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
[TBL] [Abstract] [Full Text] [Related]
8. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Latimer NR; Bell H; Abrams KR; Amonkar MM; Casey M
Cancer Med; 2016 May; 5(5):806-15. PubMed ID: 27172483
[TBL] [Abstract] [Full Text] [Related]
9. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
[TBL] [Abstract] [Full Text] [Related]
10. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract] [Full Text] [Related]
11. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract] [Full Text] [Related]
12. Trametinib: first global approval.
Wright CJ; McCormack PL
Drugs; 2013 Jul; 73(11):1245-54. PubMed ID: 23846731
[TBL] [Abstract] [Full Text] [Related]
13. Phase II study of the MEK1/mek2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
[TBL] [Abstract] [Full Text] [Related]
14. High-throughput sequencing of the melanoma genome.
Kunz M; Dannemann M; Kelso J
Exp Dermatol; 2013 Jan; 22(1):10-7. PubMed ID: 23174022
[TBL] [Abstract] [Full Text] [Related]
15. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Patel SP; Kim KB
Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
[TBL] [Abstract] [Full Text] [Related]
16. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract] [Full Text] [Related]
